Aurinia Pharmaceuticals Inc. (AUPH) FY2026 Q2 P&L / Income Statement

Aurinia Pharmaceuticals Inc. (AUPH) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenue

83,220,000 US dollars

Cost of revenue

6,555,000 US dollars

Gross profit (calculated)

76,665,000 US dollars

Operating expenses (calculated)

30,324,000 US dollars

Income from operations

46,341,000 US dollars

Other income (expense), net (calculated)

2,445,000 US dollars

Net income before income taxes

48,786,000 US dollars

Income tax expense

11,372,000 US dollars

Net income

37,414,000 US dollars

Net product sales

79,412,000 US dollars

License, collaboration and royalty revenue

3,808,000 US dollars

Research and development

13,050,000 US dollars

Selling, general and administrative

23,508,000 US dollars

Other (income) expense, net

negative 6,234,000 US dollars

Restructuring

0 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.